OrsoBio is a clinical-stage biopharmaceutical company developing first-in-class therapies to address the underlying causes of organ dysfunction in patients with severe metabolic disorders. Our dedicated, highly skilled, and cohesive team of physicians and scientists bring decades of clinical and drug development experience, from academia and industry, that serves as the foundation of our company.
CEO and Founder
Dr. Subramanian has spent more than 20 years advancing first-in-class therapies to approval. He was previously Senior Vice President and Therapeutic Area Head for Liver Diseases at Gilead Sciences where he oversaw approval of multiple therapies for viral hepatitis (Sovaldi®, Harvoni®, Epclusa®, Vosevi®, Vemlidy®) and a portfolio of compounds in NASH and other liver diseases. Previously, he was at Human Genome Sciences where he developed albumin-fusion proteins and monoclonal antibodies. He started his biotechnology career at Celera Genomics where he made major contributions to the sequencing and annotation of the human and mouse genomes.
Dr. Subramanian received his Internal Medicine training at University Hospitals of Cleveland (CWRU) and Infectious Diseases fellowship at NIAID, NIH. He holds a PhD degree from University of Michigan and MD from Armed Forces Medical College, India.
Chief Medical Officer and Head of Development
Dr. Myers is a hepatologist with over 20 years’ experience in academia and the biopharmaceutical industry. He was previously Vice President at Gilead Sciences, where he oversaw clinical development in liver fibrosis (NASH, cholestatic and alcoholic liver disease) and GI inflammation, and Associate Professor of Medicine at the University of Calgary. Dr. Myers has published over 200 peer-reviewed scientific manuscripts and was awarded a Queen Elizabeth II Diamond Jubilee Medal for his contributions to research and patient care in liver disease.
Dr. Myers received his MD and Internal Medicine training at Western University, Gastroenterology fellowship at the University of Calgary, and Hepatology fellowship at the Université de Paris VI, and holds a master’s degree in Epidemiology from the University of Calgary.
Dr. Shulman is the George R. Cowgill Professor of Medicine and Cellular & Molecular Physiology at Yale University. He is also Co-Director of the Yale Diabetes Research Center and was an Investigator of the Howard Hughes Medical Institute for 21 years. Dr. Shulman has pioneered the non-invasive assessment of glucose and fat metabolism in humans and rodent models, and his discoveries have led to paradigm shifts in our understanding of diabetes and molecular mechanisms of insulin resistance.
Dr. Shulman is the recipient of the Banting Medal for Lifetime Scientific Achievement from the American Diabetes Association. He has been elected to the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, and the National Academy of Sciences.
Dr. Auwerx is Professor at the École Polytechnique Fédérale de Lausanne (EFPL), Switzerland, where he heads the Laboratory of Integrative Systems Biology. Dr. Auwerx uses molecular physiology and systems genetics approaches to understand mitochondrial function and metabolism in health, aging, and disease. His research has spurred the development of new drugs for the treatment of metabolic, cardiovascular, renal, and neuromuscular diseases, including PPAR agonists, urolithin A, PARP inhibitors, and other NAD+ enhancers.
Dr. Auwerx was elected as a member of EMBO in 2003 and founded multiple biotech companies including Mitobridge, Carex, and PhytoDia.
Dr. Takebe is Chair of Organoid Medicine, Division of Gastroenterology, Hepatology and Nutrition Division of Developmental Biology Center for Stem Cell and Organoid Medicine (CuSTOM) Cincinnati Children’s Hospital Medical Center. Dr. Takebe is a Principal Investigator at the Takeda-CiRA joint program and full professor at Tokyo Medical and Dental University. He integrates cutting-edge stem cell biology and organoid technology to facilitate research of human biology and disease.
Dr. Takebe is on the Board of Directors for the International Society for Stem Cell Research (ISSCR) and is an elected member of American Society of Clinical Investigation (ASCI) and recipient of the Robertson Investigator Award from the New-York Stem Cell Foundation.
Board of Directors
Dr. Srinivas Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Previously, he served as a Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, Dr. Akkaraju was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager.
Prior to joining Genentech, Dr. Akkaraju was a graduate student at Stanford University, where he received his M.D. and a Ph.D. in Immunology. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University. Dr. Akkaraju also serves as a director of Intercept Pharmaceuticals and Syros Pharmaceuticals. Previously, he served as a director on the boards of Seattle Genetics, Principia Biopharma, Aravive, Inc., Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp. and Amarin Corporation.
Board of Directors
Cory joined Samsara in 2017. Prior to Samsara, Cory was a Principal at Sofinnova Ventures where he focused on biopharmaceutical investments. Cory played a central role in Sofinnova’s investments in BioClin Therapeutics, Civitas (acquired by Acorda), NextCure, NuCana Biomed (NCNA), Principia Biopharma, Spark Therapeutics (ONCE), Ziarco (acquired by Novartis), and ZS Pharma (ZSPH; acquired by AstraZeneca). Prior to Sofinnova, Cory was a Principal at Novo A/S.
Before his transition to healthcare investing, he was a Vice President in the healthcare investment banking practice at Morgan Stanley where he advised on over $12 billion of strategic and financing transactions in the biopharmaceutical and life science tools/diagnostics sectors. Prior to transitioning to life sciences finance, Cory worked as a research scientist for Roche focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases.
He received his PhD in Pharmacology from Wake Forest University School of Medicine and his MBA from the Kellogg School of Management. Cory holds a BA in Psychology and Religious Studies from Connecticut College.
Board of Directors
Muz Mansuri joined F-Prime Capital in January 2020 as a Venture Partner and is based in the Boston office. Muz works with various F-Prime team members to evaluate therapeutic and digital investment and company creation opportunities. Muz has more than 35 years of experience in various R&D roles as a senior executive within the global biopharmaceutical industry.
Prior to joining F-Prime, Muz was a member of the Executive Committee at Sanofi, as Executive Vice President, Strategy, Business Development, and Licensing. Among other responsibilities, Muz headed the Strategy, Business Development, Alliance Management and the Venture Group for Sanofi. Before this, he was at Gilead Sciences as Senior Vice President, Research and Development Strategy and Business Development. In that capacity he led the R&D Strategy, Business Development, and M&A activities for the company. Muz has served as Chief Executive Officer of several biotech companies and as a General Partner at Flagship Ventures (now Flagship Pioneering). He began his career in the pharmaceutical industry as a bench medicinal chemist with Bristol Myers.
Muz received his B.Sc. and Ph.D. in Chemistry from the University College London. He conducted postdoctoral research at UCLA and Columbia University.
Co-Founder and Chief Business and Financial Officer
OrsoBio team members collaborated with Professor Takebe in his pioneering study in Cell on the first use of en masse human liver organoids to define the genetic basis of metabolic liver disease and potential for tailored therapeutic development.